These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22949344)

  • 61. The evolution of aldosterone antagonists.
    Garthwaite SM; McMahon EG
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):27-31. PubMed ID: 15134797
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [The EMPHASIS-HF study].
    Boccanelli A; Agostoni P
    G Ital Cardiol (Rome); 2011 May; 12(5):315-8. PubMed ID: 21593949
    [No Abstract]   [Full Text] [Related]  

  • 63. Eplerenone. Pharmacia.
    Liew D; Martin J; Krum H
    Curr Opin Investig Drugs; 2003 Mar; 4(3):316-22. PubMed ID: 12744223
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Eplerenone Post-AMI Heart Failure Efficacy and survival study (EPHESUS)].
    Takata Y; Asano K; Yamashina A
    Nihon Rinsho; 2005 Mar; 63 Suppl 3():336-41. PubMed ID: 15813091
    [No Abstract]   [Full Text] [Related]  

  • 65. Eplerenone in mild heart failure.
    Pascual-Figal DA; Sanchez-Mas J; Januzzi JL
    N Engl J Med; 2011 Apr; 364(14):1370; author reply 1372. PubMed ID: 21470020
    [No Abstract]   [Full Text] [Related]  

  • 66. [Pharmacological sheet: eplerenone (Inspra), orally].
    J Pharm Belg; 2011 Sep; (3):93-4. PubMed ID: 21995102
    [No Abstract]   [Full Text] [Related]  

  • 67. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Spironolactone in heart failure--a revived role for an old drug.
    Bradley C
    Intensive Crit Care Nurs; 2000 Dec; 16(6):403-4. PubMed ID: 11091472
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
    Pitt B; Filippatos G; Gheorghiade M; Kober L; Krum H; Ponikowski P; Nowack C; Kolkhof P; Kim SY; Zannad F
    Eur J Heart Fail; 2012 Jun; 14(6):668-75. PubMed ID: 22562554
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Aldosterone antagonist therapy for chronic heart failure].
    Yamamoto T; Yano M
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):262-9. PubMed ID: 15768590
    [No Abstract]   [Full Text] [Related]  

  • 71. [Diuretic therapy in congestive heart failure--new views on spironolactone therapy].
    Haller C
    Ther Umsch; 2000 Jun; 57(6):374-9. PubMed ID: 10894022
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The risks and benefits of aldosterone antagonists.
    Sica DA
    Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Eplerenone in mild heart failure.
    Tomaschitz A; Pilz S; März W
    N Engl J Med; 2011 Apr; 364(14):1371; author reply 1372. PubMed ID: 21470018
    [No Abstract]   [Full Text] [Related]  

  • 75. Inspra improves survival for CHF patients.
    Wimett L; Laustsen G
    Nurse Pract; 2004 Jul; 29(7):56-9. PubMed ID: 15238861
    [No Abstract]   [Full Text] [Related]  

  • 76. The resurrection of spironolactone on its golden anniversary.
    Futterman LG; Lemberg L
    Am J Crit Care; 2004 Mar; 13(2):162-5. PubMed ID: 15043244
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
    Karagiannis A; Athyros VG; Mikhailidis DP
    Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
    [No Abstract]   [Full Text] [Related]  

  • 78. [Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction].
    Tsutamoto T
    Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):90-100. PubMed ID: 15277727
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart].
    MMW Fortschr Med; 2008 May; 150(22):48-9. PubMed ID: 18700263
    [No Abstract]   [Full Text] [Related]  

  • 80. [The use of aldosterone antagonists in the cardiovascular diseases].
    Trzaska E; Gumułka W; Makulska-Nowak HE
    Kardiol Pol; 2009 Jun; 67(6):667-71. PubMed ID: 19618325
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.